Radioligand therapy combines a radioactive substance with a molecule that targets cancer cells. This method directs radiation precisely to tumor sites while sparing most healthy tissue, which can help ...
@2024 - All Right Reserved.
Greater radiotracer uptake on PSMA-PET is associated with an increased likelihood of achieving a PSA decline in response to lutetium-177. The finding is from a study of 97 patients with mCRPC treated ...
Urology consultation: MRI of a male pelvis showing the bladder and the prostate. Treatment with lutetium-177 PSMA offers overall survival similar to cabazitaxel, with lower adverse event rates and ...
BOULDER, Colo. & PETACH TIKVA, Israel--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS) and Isotopia Molecular Imaging Ltd. today announced the signing of a clinical supply agreement that ...
Dr Jeremie Calais reviews the VISION trial and the implications of the data in the treatment paradigm for metastatic castration-resistant prostate cancer (mCRPC). Alicia Morgans, MD: I am curious from ...
DUBLIN, March 9, 2020 /PRNewswire/ -- The "Lutetium-177 Market and Pipeline Analysis - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering. Lutetium-177 Market and Pipeline ...
GARCHING/MUNICH, Germany & TORONTO, Canada--(BUSINESS WIRE)--ITM Isotopen Technologien München AG (ITM), a biotechnology and radiopharmaceutical group of companies, and POINT Biopharma Inc., a ...
Pluvicto is used to treat certain types of prostate cancer. It is a type of medicine called radioligand therapy. Common side effects include tiredness, dry mouth, nausea, decreased appetite, ...
Dr Jeremie Calais shares some clinical pearls for lutetium-177 PSMA 617 and how this therapy has changed the treatment landscape for patients with metastatic castration resistant prostate cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback